Table 1.

Baseline characteristics of patients with primary BRCA mutations detected in pretreatment cfDNA samples from ARIEL2

Patients with cfDNA sequenced (n = 112)Patients with primary BRCA mutations detected in cfDNA (n = 97)
Median age (range), y60.5 (33–82)60 (33–82)
Histologic classification, n (%)
 Serous108 (96.4)93 (95.9)
 Endometrioid2 (1.8)2 (2.1)
 Mixed2 (1.8)2 (2.1)
BRCA mutation type, n (%)
 Germline71 (63.4)67 (69.1)
 Somatic41 (36.6)30 (30.9)
BRCA gene with deleterious mutation, n (%)
BRCA169 (61.6)60 (61.9)
BRCA243 (38.4)37 (38.1)
Number of prior chemotherapy regimens, n (%)
 112 (10.7)8 (8.2)
 211 (9.8)10 (10.3)
 352 (46.4)47 (48.5)
 437 (33)32 (33)
Platinum response to last therapy, n (%)
 Sensitive56 (50)48 (49.5)
 Resistant44 (39.3)38 (39.2)
 Refractory12 (10.7)11 (11.3)
Median time since cancer diagnosis (range), mo49.4 (12–186.8)49.6 (12–186.8)